StockData
Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc. (ANIK) stock

ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/30
$12.85−0.07 (-0.54%)

Close on Nov 17, 2026Market cap $171.97MP/E –Yield –

Anika Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Anika Therapeutics's total assets was $183.47M at Jun 30, 2026. For fiscal 2025 it was $190.27M, down 6.2% from the year before. Over ten years it grew -2.1% a year on average. The highest annual figure on record is $365.61M in fiscal 2020.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$190.27M-6.2%
FY2024Dec 31, 2024$202.74M-25.1%
FY2023Dec 31, 2023$270.63M-22.5%
FY2022Dec 31, 2022$349.13M+0.5%
FY2021Dec 31, 2021$347.54M-4.9%
FY2020Dec 31, 2020$365.61M+10.6%
FY2019Dec 31, 2019$330.71M+18.5%
FY2018Dec 31, 2018$278.99M-1.3%
FY2017Dec 31, 2017$282.62M+17.6%
FY2016Dec 31, 2016$240.25M+1.9%
FY2015Dec 31, 2015$235.75M+22.3%
FY2014Dec 31, 2014$192.81M+23.6%
FY2013Dec 31, 2013$156.04M+9.8%
FY2012Dec 31, 2012$142.07M+6.9%
FY2011Dec 31, 2011$132.84M+3.0%
FY2010Dec 31, 2010$128.94M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$183.47M-2.2%
Q1 FY2026Mar 31, 2026$179.39M-5.9%
Q4 FY2025Dec 31, 2025$190.27M-6.2%
Q3 FY2025Sep 30, 2025$189.44M-18.1%
Q2 FY2025Jun 30, 2025$187.68M-28.5%
Q1 FY2025Mar 31, 2025$190.61M-27.7%
Q4 FY2024Dec 31, 2024$202.74M-25.1%
Q3 FY2024Sep 30, 2024$231.41M-29.5%
Q2 FY2024Jun 30, 2024$262.66M-20.1%
Q1 FY2024Mar 31, 2024$263.74M-22.2%
Q4 FY2023Dec 31, 2023$270.63M-22.5%
Q3 FY2023Sep 30, 2023$328.16M-5.6%
Q2 FY2023Jun 30, 2023$328.88M-7.1%
Q1 FY2023Mar 31, 2023$339.07M-0.9%
Q4 FY2022Dec 31, 2022$349.13M+0.5%
Q3 FY2022Sep 30, 2022$347.75M-1.5%
Q2 FY2022Jun 30, 2022$354.12M-2.5%
Q1 FY2022Mar 31, 2022$342.24M-5.5%
Q4 FY2021Dec 31, 2021$347.54M-4.9%
Q3 FY2021Sep 30, 2021$352.93M-15.2%
Q2 FY2021Jun 30, 2021$363.13M-17.6%
Q1 FY2021Mar 31, 2021$362.25M-9.2%
Q4 FY2020Dec 31, 2020$365.61M+10.6%
Q3 FY2020Sep 30, 2020$416.34M+30.3%
Q2 FY2020Jun 30, 2020$440.53M+53.3%
Q1 FY2020Mar 31, 2020$398.91M+30.1%
Q4 FY2019Dec 31, 2019$330.71M+18.5%
Q3 FY2019Sep 30, 2019$319.58M+18.7%
Q2 FY2019Jun 30, 2019$287.36M+8.3%
Q1 FY2019Mar 31, 2019$306.66M+7.9%
Q4 FY2018Dec 31, 2018$278.99M-1.3%
Q3 FY2018Sep 30, 2018$269.26M-1.4%
Q2 FY2018Jun 30, 2018$265.41M+0.2%
Q1 FY2018Mar 31, 2018$284.34M+14.9%
Q4 FY2017Dec 31, 2017$282.62M+17.6%
Q3 FY2017Sep 30, 2017$273.13M+18.2%
Q2 FY2017Jun 30, 2017$265.00M–
Q1 FY2017Mar 31, 2017$247.37M–
Q4 FY2016Dec 31, 2016$240.25M–
Q3 FY2016Sep 30, 2016$231.06M–

More Anika Therapeutics figures

See a number that looks wrong?